Evidence map›Paper›PMID 29731111›Full record

ArticleKidney international2018

Kidney-targeted inhibition of protein kinase C-α ameliorates nephrotoxic nephritis with restoration of mitochondrial dysfunction.

Nino Kvirkvelia, Malgorzata McMenamin, Marie Warren, Ravirajsinh N Jadeja, Sai Karthik Kodeboyina, Ashok Sharma, Wenbo Zhi, Paul M O'Connor, Raghavan Raju, Rudolf Lucas and 1 more

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Vitamin DCNS neuroscience & therapeutics · 2024
    Article
  3. Novel Drug Delivery Technologies and Targets for Renal Disease.Hypertension (Dallas, Tex. : 1979) · 2022
    Review
  4. Article
  5. Article
  6. Targeted Drug Delivery Systems for Kidney Diseases.Frontiers in bioengineering and biotechnology · 2021
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nino KvirkveliaDepartment of Medicine, Augusta University, Augusta, Georgia, USA.
Malgorzata McMenaminDepartment of Medicine, Augusta University, Augusta, Georgia, USA.
Marie WarrenDepartment of Pharmacology and Toxicology, Augusta University, Augusta, Georgia, USA.
Ravirajsinh N JadejaDepartment of Biochemistry and Molecular Biology, Augusta University, Augusta, Georgia, USA.
Sai Karthik KodeboyinaCenter for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia, USA.
Ashok SharmaCenter for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia, USA.
Wenbo ZhiCenter for Biotechnology and Genomic Medicine, Augusta University, Augusta, Georgia, USA.
Paul M O'ConnorDepartment of Physiology and Endocrinology, Augusta University, Augusta, Georgia, USA.
Raghavan RajuDepartment of Pharmacology and Toxicology, Augusta University, Augusta, Georgia, USA.
Rudolf LucasVascular Biology Center, Department of Pharmacology and Toxicology, Augusta University, Augusta, Georgia, USA.
Michael P MadaioDepartment of Medicine, Augusta University, Augusta, Georgia, USA. Electronic address: mmadaio@augusta.edu.
Augusta University · USAugusta University Health · US

Funding

Metabolic alterations in hemorrhagic shockR01GM122059 · NIGMS · AUGUSTA UNIVERSITY · PI RAJU, RAGHAVAN PILLAI · 2017 to 2020
$1.2M
Resveratrol as an adjunct to resuscitation fluid following hemorrhage injuryR01GM101927 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RAJU, RAGHAVAN PILLAI · 2012 to 2016
$1.1M
Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritisR01DK100564 · NIDDK · AUGUSTA UNIVERSITY · PI LUCAS, RUDOLF, MADAIO, MICHAEL P · 2015 to 2017
$684k
NIDDK NIH HHS R01 DK100564NIGMS NIH HHS R01 GM101927NIGMS NIH HHS R01 GM122059
6 · The paper itself

Abstract

To investigate the role of protein kinase C-α (PKC-α) in glomerulonephritis, the capacity of PKC-α inhibition to reverse the course of established nephrotoxic nephritis (NTN) was evaluated. Nephritis was induced by a single injection of nephrotoxic serum and after its onset, a PKC-α inhibitor was administered either systemically or by targeted glomerular delivery. By day seven, all mice with NTN had severe nephritis, whereas mice that received PKC-α inhibitors in either form had minimal evidence of disease. To further understand the underlying mechanism, label-free shotgun proteomic analysis of the kidney cortexes were performed, using quantitative mass spectrometry. Ingenuity pathway analysis revealed 157 differentially expressed proteins and mitochondrial dysfunction as the most modulated pathway. Functional protein groups most affected by NTN were mitochondrial proteins associated with respiratory processes. These proteins were down-regulated in the mice with NTN, while their expression was restored with PKC-α inhibition. This suggests a role for proteins that regulate oxidative phosphorylation in recovery. In cultured glomerular endothelial cells, nephrotoxic serum caused a decrease in mitochondrial respiration and membrane potential, mitochondrial morphologic changes and an increase in glycolytic lactic acid production; all normalized by PKC-α inhibition. Thus, PKC-α has a critical role in NTN progression, and the results implicate mitochondrial processes through restoring oxidative phosphorylation, as an essential mechanism underlying recovery. Importantly, our study provides additional support for targeted therapy to glomeruli to reverse the course of progressive disease.

Indexed as

AnimalsAntibodies, MonoclonalAutoantigensCollagen Type IVDisease Models, AnimalDrug Delivery SystemsFemaleGlomerulonephritisHumansHybridomasImmune SeraImmunoglobulin FragmentsImmunoglobulin GKidney GlomerulusMiceMice, Inbred C57BLAntibodies, MonoclonalAutoantigensCollagen Type IVImmune SeraImmunoglobulin FragmentsImmunoglobulin GPrkca protein, mouseProtein Kinase C-alphaProtein Kinase Inhibitorstype IV collagen alpha3 chainglomerular endothelial cellsmitochondrial dysfunctionnephritisPKC-α inhibitionproteomicstargeted delivery

Identifiers

PMID29731111
PMCPMC6084791
OpenAlexW2801561822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.